INTRODUCTION: International Myeloma Working Group (IMWG) criteria require 24-hour urine specimens as part of response assessments, which can be cumbersome for p
Emily Whitehead has been in remission since 2012 after receiving CAR T-cell therapy to treat her leukemia.
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value enter…
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and…
“Today’s unanimous ODAC vote – 12-0 in favor – is a milestone for the field of multiple myeloma,” said Dr. C. Ola Landgren, director of…
Although 64% of patients seeking IO consultation reported clinically significant SD, only 11% were seeking integrative approaches for managing SD. ESAS fatigue, hot flashes, well-being,…
By using this website, you consent to us using cookies as described in this policy
Blood Cancer Journal – Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
About 15 years ago, Carl Ola Landgren, M.D. Ph.D., noticed an encouraging yet potentially concerning trend in the treatment of multiple myeloma. | At an…
Traditional prognostic models for newly diagnosed patients with multiple myeloma (MM), including International Staging System criteria and number of high-risk chromosomal abnormalities, are based on…
Chimeric antigen receptor-modified T cell (CAR-T) therapy has become a critical part of the armamentarium for the treatment of relapsed/refractory hematologic malignancies. As our experience…
